Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Rajotte, Paul
Bordeleau, Jean-Marc
Tétreault, Léon
Doucet, Pierre
and
Rajotte, Elisabeth
1966.
A Double-Blind Comparative Study of Opipramol and Amitriptyline in Neurotic and Endogenous Depressions.
Canadian Psychiatric Association Journal,
Vol. 11,
Issue. 1_suppl,
p.
159.
Leyburn, Peter
1967.
A CRITICAL LOOK AT ANTIDEPRESSANT DRUG TRIALS.
The Lancet,
Vol. 290,
Issue. 7526,
p.
1135.
Grosz, Hanus J.
1968.
The Relation Between Neurosis and Psychosis:.
British Journal of Psychiatry,
Vol. 114,
Issue. 507,
p.
189.
Hays, P.
and
Steinert, Jack
1969.
A Blind Comparative Trial of Nortriptyline and Isocarboxazid in Depressed Outpatients*.
Canadian Psychiatric Association Journal,
Vol. 14,
Issue. 3,
p.
307.
Geisler, Arne
1970.
Svigtende overholdelse af behandlingen som en fejlkilde ved bedømmelse af et antidepressivums (amitriptylin) effekt ved reaktive depressioner.
Nordisk Psykiatrisk Tidsskrift,
Vol. 24,
Issue. 3,
p.
221.
Colville, J. B.
and
Trounce, J. R.
1970.
A Guide to Drugs in Current Use.
p.
40.
Kellner, Robert
1972.
Part 2. Improvement criteria in drug trials with neurotic patients.
Psychological Medicine,
Vol. 2,
Issue. 1,
p.
73.
Raskin, Allen
and
Crook, Thomas H.
1976.
The endogenous—neurotic distinction as a predictor of response to antidepressant drugs.
Psychological Medicine,
Vol. 6,
Issue. 1,
p.
59.
PAYKEL, E.S.
1977.
Handbook of Studies on Depression.
p.
21.
Mindham, R.H.
1982.
Drugs in Psychiatric Practice.
p.
177.
White, Kerrin
Razani, Javad
Cadow, Barbara
Gelfand, Ronald
Palmer, Ruby
Simpson, George
and
Sloane, R. Bruce
1984.
Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.
Psychopharmacology,
Vol. 82,
Issue. 3,
p.
258.
Davis, John M
Janicak, Philip C
and
Bruninga, Keith
1987.
The Efficacy of MAO Inhibitors in Depression: A Meta-Analysis.
Psychiatric Annals,
Vol. 17,
Issue. 12,
p.
825.
O'Brien, Sinead
and
McKeon, Patrick
1990.
Current issues in monoamine oxidase inhibitor treatment.
Irish Journal of Psychological Medicine,
Vol. 7,
Issue. 2,
p.
159.
Gerlach, M.
Riederer, P.
Schoerlin, M. P.
Guentert, T. W.
Waldmeier, P.
Kettler, R.
Cesura, A.
Richards, J. G.
Da Prada, M.
Laux, G.
Becker, T.
Bieck, P. R.
and
Schmauß, M.
1993.
Neuro-Psychopharmaka.
p.
269.
Barbui, Corrado
and
Hotopf, Matthew
2001.
Amitriptylinev.the rest: still the leading antidepressant after 40 years of randomised controlled trials.
British Journal of Psychiatry,
Vol. 178,
Issue. 2,
p.
129.
Guaiana, G
Barbui, C
Hotopf, M
and
Barbui, Corrado
2003.
The Cochrane Database of Systematic Reviews.
Guaiana, Giuseppe
Barbui, Corrado
and
Hotopf, Matthew
2007.
Amitriptyline for depression.
Cochrane Database of Systematic Reviews,
Ricken, Roland
Ulrich, Sven
Schlattmann, Peter
and
Adli, Mazda
2017.
Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression.
European Neuropsychopharmacology,
Vol. 27,
Issue. 8,
p.
714.
Ulrich, Sven
Ricken, Roland
Buspavanich, Pichit
Schlattmann, Peter
and
Adli, Mazda
2020.
Efficacy and Adverse Effects of Tranylcypromine and Tricyclic Antidepressants in the Treatment of Depression.
Journal of Clinical Psychopharmacology,
Vol. 40,
Issue. 1,
p.
63.
Meyer, Jeffrey H.
Matveychuk, Dmitriy
Holt, Andrew
Santhirakumar, Apitharani
and
Baker, Glen B.
2021.
NeuroPsychopharmacotherapy.
p.
1.
eLetters
No eLetters have been published for this article.